AKT1 and triple-negative breast carcinoma: Interestingly, MCF10A did not react to either of the treatments nor to AQP3 silencing with changes in the PI3K/Akt pathway, which is in line with previously published data using an Akt inhibitor, which affected viability of triple-negative breast cancer cell lines, but not MCF10A [32].